Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that the replacement of Gly<sup>11</sup> with Sar<sup&...

Full description

Bibliographic Details
Main Authors: Ayman Abouzayed, Panagiotis Kanellopoulos, Alisa Gorislav, Vladimir Tolmachev, Theodosia Maina, Berthold A. Nock, Anna Orlova
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Biomolecules
Subjects:
prostate cancer
GRPR antagonist
theranostics
PC-3 cells
neprilysin
Online Access:https://www.mdpi.com/2218-273X/13/7/1134

Internet

https://www.mdpi.com/2218-273X/13/7/1134

Similar Items